Last modified: January 10, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
Helix BioPharma Corporation is developing innovative medicines mainly in the areas of cancer prevention and treatment.
Helix is focused on the development of two product candidates: The Company’s most advanced initiative is its Topical Interferon Alpha-2b, under clinical testing as a preventative therapeutic against cervical cancer development as well as a treatment for ano-genital warts, both of which are conditions caused by human papillomavirus (HPV) infections.
Helix’s second initiative is its L-DOS47 for the treatment of the most common form of lung cancer, lung adenocarcinoma. L-DOS47 is based upon Helix’s patented new broad spectrum therapeutic approach for the destruction of cancer cells. L-DOS47 is currently under preclinical development in preparation for clinical testing.
Helix is headquartered in Toronto, Canada and listed on the Toronto Stock Exchange (TSX) under the symbol: HBP
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Helix BioPharma Corporation Job Trends | Helix BioPharma Corporation Jobs |
- Biotech Showcase 2010 - Presenting Companies (3 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Helix BioPharma Corporation has been added to the Ecosystem. |